These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 12161284)

  • 1. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.
    Ishida M; Iwai Y; Tanaka Y; Okazaki T; Freeman GJ; Minato N; Honjo T
    Immunol Lett; 2002 Oct; 84(1):57-62. PubMed ID: 12161284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
    J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of programmed death 1 ligands by murine T cells and APC.
    Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
    J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.
    He YF; Zhang GM; Wang XH; Zhang H; Yuan Y; Li D; Feng ZH
    J Immunol; 2004 Oct; 173(8):4919-28. PubMed ID: 15470033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
    Carter L; Fouser LA; Jussif J; Fitz L; Deng B; Wood CR; Collins M; Honjo T; Freeman GJ; Carreno BM
    Eur J Immunol; 2002 Mar; 32(3):634-43. PubMed ID: 11857337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation.
    Kanai T; Totsuka T; Uraushihara K; Makita S; Nakamura T; Koganei K; Fukushima T; Akiba H; Yagita H; Okumura K; Machida U; Iwai H; Azuma M; Chen L; Watanabe M
    J Immunol; 2003 Oct; 171(8):4156-63. PubMed ID: 14530338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death-1 targeting can promote allograft survival.
    Ozkaynak E; Wang L; Goodearl A; McDonald K; Qin S; O'Keefe T; Duong T; Smith T; Gutierrez-Ramos JC; Rottman JB; Coyle AJ; Hancock WW
    J Immunol; 2002 Dec; 169(11):6546-53. PubMed ID: 12444166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.
    Menke J; Lucas JA; Zeller GC; Keir ME; Huang XR; Tsuboi N; Mayadas TN; Lan HY; Sharpe AH; Kelley VR
    J Immunol; 2007 Dec; 179(11):7466-77. PubMed ID: 18025191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.
    Zhu B; Guleria I; Khosroshahi A; Chitnis T; Imitola J; Azuma M; Yagita H; Sayegh MH; Khoury SJ
    J Immunol; 2006 Mar; 176(6):3480-9. PubMed ID: 16517716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential binding properties of B7-H1 and B7-DC to programmed death-1.
    Youngnak P; Kozono Y; Kozono H; Iwai H; Otsuki N; Jin H; Omura K; Yagita H; Pardoll DM; Chen L; Azuma M
    Biochem Biophys Res Commun; 2003 Aug; 307(3):672-7. PubMed ID: 12893276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response.
    Gu T; Zhu YB; Chen C; Li M; Chen YJ; Yu GH; Ge Y; Zhou SY; Zhou H; Huang Y; Qiu YH; Zhang XG
    Cell Mol Immunol; 2008 Feb; 5(1):33-9. PubMed ID: 18318992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue expression of PD-L1 mediates peripheral T cell tolerance.
    Keir ME; Liang SC; Guleria I; Latchman YE; Qipo A; Albacker LA; Koulmanda M; Freeman GJ; Sayegh MH; Sharpe AH
    J Exp Med; 2006 Apr; 203(4):883-95. PubMed ID: 16606670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
    Latchman Y; Wood CR; Chernova T; Chaudhary D; Borde M; Chernova I; Iwai Y; Long AJ; Brown JA; Nunes R; Greenfield EA; Bourque K; Boussiotis VA; Carter LL; Carreno BM; Malenkovich N; Nishimura H; Okazaki T; Honjo T; Sharpe AH; Freeman GJ
    Nat Immunol; 2001 Mar; 2(3):261-8. PubMed ID: 11224527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
    Lee I; Wang L; Wells AD; Ye Q; Han R; Dorf ME; Kuziel WA; Rollins BJ; Chen L; Hancock WW
    J Immunol; 2003 Dec; 171(12):6929-35. PubMed ID: 14662900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.
    Bennett F; Luxenberg D; Ling V; Wang IM; Marquette K; Lowe D; Khan N; Veldman G; Jacobs KA; Valge-Archer VE; Collins M; Carreno BM
    J Immunol; 2003 Jan; 170(2):711-8. PubMed ID: 12517932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.
    Keir ME; Latchman YE; Freeman GJ; Sharpe AH
    J Immunol; 2005 Dec; 175(11):7372-9. PubMed ID: 16301644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation.
    Bu DX; Tarrio M; Maganto-Garcia E; Stavrakis G; Tajima G; Lederer J; Jarolim P; Freeman GJ; Sharpe AH; Lichtman AH
    Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1100-7. PubMed ID: 21393583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation.
    Kuipers H; Muskens F; Willart M; Hijdra D; van Assema FB; Coyle AJ; Hoogsteden HC; Lambrecht BN
    Eur J Immunol; 2006 Sep; 36(9):2472-82. PubMed ID: 16917960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3.
    Seko Y; Yagita H; Okumura K; Azuma M; Nagai R
    Cardiovasc Res; 2007 Jul; 75(1):158-67. PubMed ID: 17434153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function.
    Terawaki S; Tanaka Y; Nagakura T; Hayashi T; Shibayama S; Muroi K; Okazaki T; Mikami B; Garboczi DN; Honjo T; Minato N
    Int Immunol; 2007 Jul; 19(7):881-90. PubMed ID: 17606978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.